Harvard Bioscience, Inc. to Participate in the Sidoti Micro Cap Conference
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Harvard Bioscience (HBIO) has announced its participation in the upcoming Sidoti Micro Cap Virtual Conference on January 22nd, 2025. The company's Chairman and CEO Jim Green, along with CFO Jennifer Cote, will deliver a presentation at 10:00 am ET.
The presentation will be accessible through a live webcast via the investor relations section of Harvard Bioscience's website. Interested parties can view the presentation replay after its conclusion. One-on-one meetings can be arranged through the conference organizers.
Details
News Market Reaction – HBIO
The recorded move for HBIO in the trading session of this news was +2.02%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
HOLLISTON, Mass., Jan. 13, 2025 (GLOBE NEWSWIRE) -- Harvard Bioscience, Inc. (Nasdaq: HBIO) today announced that Jim Green, Chairman and Chief Executive Officer, and Jennifer Cote, Chief Financial Officer, will be participating in the Sidoti Micro Cap Virtual Conference on January 22nd, 2025, with a presentation time of 10:00 am ET.
The presentation will be webcast live and can be accessed through the investor relations section of the Harvard Bioscience website: https://investor.harvardbioscience.com/events-and-presentations. A replay will be available on the company’s website shortly after the presentation has concluded.
To schedule a one-on-one meeting, please contact the conference organizers directly.
About Harvard Bioscience, Inc.
Harvard Bioscience, Inc. is a leading developer, manufacturer and seller of technologies, products and services that enable fundamental advances in life science applications, including research, pharmaceutical and therapy discovery, bio-production and preclinical testing for pharmaceutical and therapy development. Our customers range from renowned academic institutions and government laboratories to the world’s leading pharmaceutical, biotechnology and contract research organizations. With operations in North America, Europe, and China, we sell through a combination of direct and distribution channels to customers around the world. For more information, please visit our website at www.harvardbioscience.com
Company Contact:
Harvard Bioscience
Jennifer Cote, Chief Financial Officer
(508) 893-3120
Investor Contacts:
Three Part Advisors
Sandy Martin / Erol Girgin
HBIO@threepa.com
(214) 616-2207
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.